Status:
COMPLETED
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
St. Olavs Hospital
South-Eastern Norway Regional Health Authority
Conditions:
Non-ST Elevation Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Acute coronary syndromes (ACS) are still associated with high morbidity and mortality, despite several improvements in their management. This may indicate that important pathogenic mechanisms contribu...
Eligibility Criteria
Inclusion
- NSTEMI (ESC Type 1)
- Age 18-80 years
- Troponin T \>/= 30 ng/ml
- Informed consent to participation
Exclusion
- STEMI
- Known cardiac disease, except coronary disease (cardiomyopathy, heart failure with known EF \< 45%, severe valvular heart disease attending regular follow-up, recent PCI/ACB (\< 3 months))
- Hemodynamic and/or respiratory instability
- Cardiac arrest in acute phase
- Concurrent condition affecting/potentially affecting CRP (infection, malignancy, autoimmune disease)
- Recent major surgery (\< 3 months)
- Recent/concurrent immunosuppressant treatment (\< 2 weeks, except NSAIDs)
- Severe renal failure (eGFR \< 30 ml/min)
- Pregnancy
- Contraindications to any study investigations and/or medication.
- Expected non-adherence to study protocol
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01491074
Start Date
August 1 2011
End Date
April 1 2014
Last Update
May 19 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Oslo County, Norway, 0424
2
St Olavs Hospital
Trondheim, Sør-Trøndelag, Norway, 7006